Search research articles
Contact Us
Filters
Showing results (511-520 of 616) with videos related to
Page
of 62
Sort By:
European Journal of Heart Failure
|
February 17, 2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial
Jawad H Butt, Jose C Nicolau, Subodh Verma, et al.
Circulation
|
November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
Benjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology
|
August 22, 2015
Valve-Related Hemodynamics Mediate Human Bicuspid Aortopathy: Insights From Wall Shear Stress Mapping
David G Guzzardi, Alex J Barker, Pim van Ooij, et al.
BMJ Open
|
June 12, 2017
Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 randomised trial
Vinay Garg, Mark D Peterson, Michael Wa Chu, et al.
Circulation
|
November 15, 2021
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Javed Butler, Gerasimos Filippatos, Tariq Jamal Siddiqi, et al.
The Canadian Journal of Cardiology
|
December 16, 2019
Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results
Sean Kang, Subodh Verma, Ali Fatehi Hassanabad, et al.
European Heart Journal
|
January 9, 2021
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
Javed Butler, Stefan D Anker, Gerasimos Filippatos, et al.
Med (New York, N.Y.)
|
March 29, 2024
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial
Ehab Bakbak, Aishwarya Krishnaraj, Deepak L Bhatt, et al.
Circulation
|
August 23, 2019
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma, C David Mazer, Andrew T Yan, et al.
NEJM Evidence
|
February 6, 2024
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery
Deepak L Bhatt, Charles V Pollack, C David Mazer, et al.
Page
of 62
Search research articles
Search
Showing results (511-520 of 616) with videos related to
Sort By:
Page
of 62
European Journal of Heart Failure
|
February 17, 2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial
Jawad H Butt, Jose C Nicolau, Subodh Verma, et al.
Circulation
|
November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
Benjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology
|
August 22, 2015
Valve-Related Hemodynamics Mediate Human Bicuspid Aortopathy: Insights From Wall Shear Stress Mapping
David G Guzzardi, Alex J Barker, Pim van Ooij, et al.
BMJ Open
|
June 12, 2017
Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 randomised trial
Vinay Garg, Mark D Peterson, Michael Wa Chu, et al.
Circulation
|
November 15, 2021
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Javed Butler, Gerasimos Filippatos, Tariq Jamal Siddiqi, et al.
The Canadian Journal of Cardiology
|
December 16, 2019
Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results
Sean Kang, Subodh Verma, Ali Fatehi Hassanabad, et al.
European Heart Journal
|
January 9, 2021
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
Javed Butler, Stefan D Anker, Gerasimos Filippatos, et al.
Med (New York, N.Y.)
|
March 29, 2024
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial
Ehab Bakbak, Aishwarya Krishnaraj, Deepak L Bhatt, et al.
Circulation
|
August 23, 2019
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma, C David Mazer, Andrew T Yan, et al.
NEJM Evidence
|
February 6, 2024
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery
Deepak L Bhatt, Charles V Pollack, C David Mazer, et al.
Page
of 62